Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

The Biology and Therapeutic Implications of Tumor Dormancy and Reactivation.

Yadav AS, Pandey PR, Butti R, Radharani NNV, Roy S, Bhalara SR, Gorain M, Kundu GC, Kumar D.

Front Oncol. 2018 Mar 19;8:72. doi: 10.3389/fonc.2018.00072. eCollection 2018. Review.

2.

Cancer stem cells as key drivers of tumour progression.

Ayob AZ, Ramasamy TS.

J Biomed Sci. 2018 Mar 6;25(1):20. doi: 10.1186/s12929-018-0426-4. Review.

3.

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer.

Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL, Kumar S, Moylan VJ, Brady CM, Van Swearingen AE, Marron D, Gupta GP, Thorne LB, Kieran N, Livasy C, Mardis ER, Parker JS, Chen M, Anders CK, Carey LA, Perou CM.

J Clin Invest. 2018 Apr 2;128(4):1371-1383. doi: 10.1172/JCI96153. Epub 2018 Feb 26.

PMID:
29480819
4.

Cancer Stem Cells, Bone and Tumor Microenvironment: Key Players in Bone Metastases.

Roato I, Ferracini R.

Cancers (Basel). 2018 Feb 20;10(2). pii: E56. doi: 10.3390/cancers10020056. Review.

5.

AR Expression in Breast Cancer CTCs Associates with Bone Metastases.

Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S.

Mol Cancer Res. 2018 Apr;16(4):720-727. doi: 10.1158/1541-7786.MCR-17-0480. Epub 2018 Feb 16.

PMID:
29453314
6.

Complete response in advanced breast cancer patient treated with a combination of capecitabine, oral vinorelbine and dasatinib.

Sgroi V, Bassanelli M, Roberto M, Iannicelli E, Porrini R, Pellegrini P, Tafuri A, Marchetti P.

Exp Hematol Oncol. 2018 Jan 24;7:2. doi: 10.1186/s40164-018-0094-9. eCollection 2018.

7.

Intrinsic subtypes and bladder cancer metastasis.

McConkey DJ, Choi W, Ochoa A, Dinney CPN.

Asian J Urol. 2016 Oct;3(4):260-267. doi: 10.1016/j.ajur.2016.09.009. Epub 2016 Sep 23. Review.

8.

Tumor cell dormancy as an adaptive cell stress response mechanism.

Vera-Ramirez L, Hunter KW.

F1000Res. 2017 Dec 14;6:2134. doi: 10.12688/f1000research.12174.1. eCollection 2017. Review.

9.

Notch and its oncogenic activity in human malignancies.

Brzozowa-Zasada M, Piecuch A, Michalski M, Segiet O, Kurek J, Harabin-Słowińska M, Wojnicz R.

Eur Surg. 2017;49(5):199-209. doi: 10.1007/s10353-017-0491-z. Epub 2017 Sep 18. Review.

10.

Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.

Orive-Ramos A, Seoane S, Ocaña A, Pandiella A, Montero JC.

Mol Oncol. 2017 Dec;11(12):1788-1805. doi: 10.1002/1878-0261.12145. Epub 2017 Oct 31.

11.

Adaptive metabolic rewiring to chronic SFK inhibition.

Pinedo-Carpio E, Davidson D, Martinez Marignac VL, Panasci J, Aloyz R.

Oncotarget. 2016 Mar 17;8(40):66758-66768. doi: 10.18632/oncotarget.8146. eCollection 2017 Sep 15.

12.

Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?

Farach-Carson MC, Lin SH, Nalty T, Satcher RL.

Front Oncol. 2017 Aug 7;7:163. doi: 10.3389/fonc.2017.00163. eCollection 2017. Review.

13.

Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.

Gdowski AS, Ranjan A, Vishwanatha JK.

J Exp Clin Cancer Res. 2017 Aug 11;36(1):108. doi: 10.1186/s13046-017-0578-1. Review.

14.

Roles of Wnt Target Genes in the Journey of Cancer Stem Cells.

Kim JH, Park SY, Jun Y, Kim JY, Nam JS.

Int J Mol Sci. 2017 Jul 25;18(8). pii: E1604. doi: 10.3390/ijms18081604. Review.

15.

The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.

Appel CK, Gallego-Pedersen S, Andersen L, Blancheflor Kristensen S, Ding M, Falk S, Sayilekshmy M, Gabel-Jensen C, Heegaard AM.

Sci Rep. 2017 Jul 6;7(1):4792. doi: 10.1038/s41598-017-05029-1.

16.

Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status.

Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S, Hortobagyi GN, Pusztai L, Symmans WF, Ueno NT.

J Cancer. 2017 Apr 9;8(6):1045-1052. doi: 10.7150/jca.13690. eCollection 2017.

17.

Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis.

Bado I, Gugala Z, Fuqua SAW, Zhang XH.

Oncogene. 2017 Aug 10;36(32):4527-4537. doi: 10.1038/onc.2017.94. Epub 2017 Apr 3. Review.

18.

Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis.

Xie HY, Shao ZM, Li DQ.

Chin J Cancer. 2017 Mar 29;36(1):36. doi: 10.1186/s40880-017-0202-y. Review.

19.

NRAS destines tumor cells to the lungs.

Giannou AD, Marazioti A, Kanellakis NI, Giopanou I, Lilis I, Zazara DE, Ntaliarda G, Kati D, Armenis V, Giotopoulou GA, Krontira AC, Lianou M, Agalioti T, Vreka M, Papageorgopoulou M, Fouzas S, Kardamakis D, Psallidas I, Spella M, Stathopoulos GT.

EMBO Mol Med. 2017 May;9(5):672-686. doi: 10.15252/emmm.201606978.

20.

Facial cutaneo-mucosal venous malformations can develop independently of mutation of TEK gene but may be associated with excessive expression of Src and p-Src.

Brahami N, Subramaniam S, Al-Ddafari MS, Elkaim C, Harmand PO, Sari BE, Lefranc G, Aribi M.

J Negat Results Biomed. 2017 Mar 20;16(1):9. doi: 10.1186/s12952-017-0072-5.

Supplemental Content

Support Center